Evaluation of Safety and Efficacy of Allo GDA-201 Natural Killer (NK) Cells in Patients With Relapsed/Refractory B Cell NHL

Inclusion Criteria

• Patients must have relapsed/refractory FL or HGBCL/DLBCL that has failed conventional therapy defined as follows:
• Received at least 2 prior lines of therapy
• Transplant ineligible patients allowed assuming they meet criterion a.
• Patients who received prior chimeric antigen receptor modified T-cells (CAR-T) cell therapy or are considered ineligible for CAR-T therapy per the investigator's discretion
• FL transformed to HGBCL: Must have received at least 1 line of therapy after transformation to DLBCL/HGBCL
• Patients must be at least 18 years of age
• Patients must have adequate hematologic, hepatic, renal, cardiac and pulmonary function prior to any study treatment.

Exclusion Criteria

• Central Nervous System (CNS) lymphoma
• Time between previous treatment and first dose of study treatment (rituximab):
• Allogeneic hematopoietic stem cell transplantation (HSCT) < 6 months prior to study treatment
• Autologous HSCT < 3 months prior to study treatment
• CAR-T < 2 months prior to study treatment